<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963441</url>
  </required_header>
  <id_info>
    <org_study_id>IDx-DR1</org_study_id>
    <nct_id>NCT02963441</nct_id>
  </id_info>
  <brief_title>A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy</brief_title>
  <official_title>A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDx LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IDx LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes affects 30.3 million people or 9.3% of the population of the United States. Results&#xD;
      of a study by the Eye Diseases Prevalence Research Group reveal that 40% of diabetes patients&#xD;
      have some degree of diabetic retinopathy (DR) and that as many as 8% have severe,&#xD;
      vision-threatening forms of DR. Early laser photocoagulation in high-risk proliferative&#xD;
      diabetic retinopathy (PDR) has been shown to decrease the relative risk of vision loss by as&#xD;
      much as 52%. Injections of anti-VEGF agents preserve and improve vision in people with PDR&#xD;
      and/or diabetic macular edema. Despite effective treatment however, tens of thousands of&#xD;
      people with diabetes are going blind each year largely because they don't undergo annual&#xD;
      screening for retinopathy. Currently, less than 50%-60% of people with diabetes have a yearly&#xD;
      eye exam and there may not be enough eye specialists to see the balance.&#xD;
&#xD;
      The IDx-DR System is intended for use by health care providers to automatically detect more&#xD;
      than mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with&#xD;
      diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is&#xD;
      indicated for use with the Topcon NW400.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From January 2017 to July 2017, 900 participants were prospectively enrolled in this&#xD;
      observational study at 10 primary care practice sites throughout the United States. The study&#xD;
      was approved by the institutional review board for each site, and all participants provided&#xD;
      written informed consent. The study, which was funded by IDx LLC, was designed by the authors&#xD;
      with input from the U.S. Food and Drug Administration (FDA) on the endpoints, statistical&#xD;
      testing, and study design. Emmes Corp, a contract research organization (CRO), provided&#xD;
      overall project management, including data management and independent monitoring and auditing&#xD;
      services for all sites. CCR, Inc., an Algorithm Integrity Provider (AIP), was contracted to&#xD;
      lock the AI system, hold any intermediate and final results and images in escrow, and&#xD;
      interdict access to these by the Sponsor, from prior to the start of the study until final&#xD;
      data lock. Because the Sponsor was thus interdicted from access to the AI system, the AIP&#xD;
      performed all necessary maintenance and servicing activities during the study as well as&#xD;
      throughout closeout.&#xD;
&#xD;
      The target population was asymptomatic persons, ages of 22 and older, who had been diagnosed&#xD;
      with diabetes and had not been previously diagnosed with DR. A diagnosis of diabetes was&#xD;
      defined as meeting the criteria established by either the World Health Organization (WHO) or&#xD;
      the American Diabetes Association (ADA); Hemoglobin A1c (HbA1c) ≥ 6.5% based on repeated&#xD;
      assessments; Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) based on repeated&#xD;
      assessments; Oral Glucose Tolerance Test (OGTT) with two-hour plasma glucose (2-hr PG) ≥ 200&#xD;
      mg/dL (11.1 mmol/L) using the equivalent of an oral 75 g anhydrous glucose dose dissolved in&#xD;
      water; or symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose&#xD;
      (RPG) ≥ 200 mg/dL (11.1 mmol/L).&#xD;
&#xD;
      To help enroll a sufficient number of mtmDR participants for the evaluation of sensitivity, a&#xD;
      stepwise enrichment strategy, as indicated in the prespecified protocol, was utilized&#xD;
      mid-study to recruit sufficient numbers of mtmDR participants. The enrichment strategy sought&#xD;
      higher risk participants with elevated HbA1c (&gt;9.0%) levels or elevated Fasting Plasma&#xD;
      Glucose; this enrichment was independently activated by the statistician while always&#xD;
      remaining masked to the AI system outputs and the ETDRS disease levels. To account for any&#xD;
      unintentional spectrum bias in the no/mild population, the study pre-defined a specificity&#xD;
      outcome parameter to correct for any potential spectrum bias resulting from this enrichment&#xD;
      strategy as co-primary.&#xD;
&#xD;
      All primary care sites in the study identified one or more inhouse operator trainees to&#xD;
      perform the AI system protocol. After installation of the equipment by the Sponsor at the&#xD;
      site, but before any participant was recruited, AI system operator trainees had to attest&#xD;
      that they had not previously performed ocular imaging. Also, before start of study&#xD;
      recruitment at each site, AI system operator trainees underwent a one-time standardized 4 h&#xD;
      training program. They were trained how to acquire images, how to improve image quality if&#xD;
      the AI system gave an insufficient quality output, and how to put images for analysis into&#xD;
      the AI system. No additional training was provided to any of the AI system operators for the&#xD;
      duration of the study. Independently, FPRC certified expert photographers were identified in&#xD;
      geographic locations close to each site by the CRO, and documented 4W-D FPRC certification&#xD;
      was required before any participant was imaged. The CRO independently completed site&#xD;
      initiation visits at each site to ensure each site met all the good clinical practice&#xD;
      requirements prior to start of enrollment.&#xD;
&#xD;
      Study protocol. All participants gave written informed consent to participate in both the AI&#xD;
      system protocol, as well as the FPRC imaging protocol, using two different cameras:&#xD;
&#xD;
      The AI system protocol consisted of the following steps:&#xD;
&#xD;
        1. Operator takes images with a nonmydriatic retinal camera (NW400, Topcon Medical Systems,&#xD;
           Oakland, NJ) according to a standardized imaging protocol with one disc and one fovea&#xD;
           centered 45° image per eye;&#xD;
&#xD;
        2. Operator submits images to the AI system for automated image quality and protocol&#xD;
           adherence evaluation;&#xD;
&#xD;
        3. If the AI system outputs insufficient quality, steps 1-2 are repeated until sufficient&#xD;
           quality is output or 3 attempts were made. If the AI system still indicates that images&#xD;
           are of insufficient quality, the participant's pupils are dilated with tropicamide 1.0%&#xD;
           eyedrops, (provided by the Sponsor at each site), until the pupil diameter is at least&#xD;
           5mm in each eye or 30 minutes have passed, and steps 1-2 are repeated until sufficient&#xD;
           quality is output or 3 attempts were made. If the AI system still outputs that images&#xD;
           are of insufficient quality, the AI system output of insufficient quality is&#xD;
           automatically provided to the CRO via secure data transfer;&#xD;
&#xD;
        4. Whenever the AI system indicates sufficient quality, the AI system disease level output&#xD;
           (either mtmDR detected or mtmDR not detected) is automatically provided to the CRO via&#xD;
           secure data transfer; the final AI system output provided to the CRO after this protocol&#xD;
           was mtmDR detected, mtmDR not detected or insufficient quality&#xD;
&#xD;
      The FPRC imaging protocol was then conducted, and consisted of the following steps, all&#xD;
      performed by an FPRC certified photographer:&#xD;
&#xD;
        1. If participant is not already dilated, dilating eye drops of tropicamide 1.0% are&#xD;
           administered;&#xD;
&#xD;
        2. Digital widefield stereoscopic fundus photography is performed, using a camera capable&#xD;
           of widefield photography, (Maestro, Topcon Medical Systems, Oakland, NJ) according to&#xD;
           the FPRC 4W-D stereo protocol, by an FPRC certified photographer;&#xD;
&#xD;
        3. Anterior segment photography for media opacity assessment is performed according to the&#xD;
           Age Related Eye Disease Study, by an FPRC certified photographer;&#xD;
&#xD;
        4. OCT of the macula is performed using a standard OCT system capable of producing a cube&#xD;
           scan containing at least 121 B scans, (Maestro, Topcon Medical Systems, Oakland, NJ)&#xD;
           according to the FPRC OCT protocol, by an FPRC certified photographer.&#xD;
&#xD;
      The FPRC certified photographers were masked to the AI system outputs at all times.&#xD;
&#xD;
      Reference standards. The FPRC grading protocol consisted of determination of ETDRS Severity&#xD;
      Scale (SS) levels for fundus photographs and standardized OCT grading, as follows: the 4W-D&#xD;
      images were read by three experienced and validated readers at the FPRC according to the well&#xD;
      established ETDRS SS, using a majority voting paradigm. The macular OCT images were evaluated&#xD;
      for the presence of center-involved DME by experienced readers at the FPRC according to the&#xD;
      DRCR grading paradigm. For each participant, the ETDRS levels were mapped to mtmDR+(ETDRS&#xD;
      level 35 or higher and /or DME present), or mtmDR- (ETDRS level 10-20 and DME absent), taking&#xD;
      the worst of two eyes to correspond to the outputs of the AI system at the participant&#xD;
      level.16 To measure sensitivity for the cases requiring immediate followup, called vision&#xD;
      threatening DR, we defined vtDR + as ETDRS level 53 or higher, and/ or DME present, See&#xD;
      Supplemental Table 2 for the mapping from ETDRS and DME levels to dichotomous mtmDR- and&#xD;
      mtmDR +and vtDR+. Because DME can be identified both on the basis of retinal thickening on&#xD;
      stereoscopic fundus photographs, as well as on the basis of retinal thickening on OCT, we&#xD;
      separately analyzed both. Stereoscopic fundus based Clinically Significant DME (CSDME) was&#xD;
      identified if there was either retinal thickening or adjacent hard exudates &lt; 600 μm from the&#xD;
      foveal center, or a zone of retinal thickening &gt; 1 disc area, part of which is less than 1&#xD;
      disc diameter from the foveal center, according to the FPRC, in any eye. OCT based&#xD;
      center-involved DME was identified if a participant had central subfield (a 1.0mm circle&#xD;
      centered on the fovea) thickness that was &gt;300 μm according to the FPRC, in any eye.20&#xD;
      Accordingly, we further specify the definition of mtmDR where relevant:&#xD;
&#xD;
      fundus mtmDR+ is defined as&#xD;
&#xD;
        -  ETDRS level ≥ 35 (determined from fundus photographs)and/or&#xD;
&#xD;
        -  CSDME (determined from fundus photographs)&#xD;
&#xD;
      and multimodal mtmDR+is defined as:&#xD;
&#xD;
        -  ETDRS level ≥ 35 (determined from fundus photographs), and / or&#xD;
&#xD;
        -  CSDME (determined from fundus photographs) and / or&#xD;
&#xD;
        -  center-involved DME (determined from OCT).&#xD;
&#xD;
      and similarly for vtDR + . FPRC readers were masked to the AI system outputs at all times,&#xD;
      masked to the fundus photograph reading when evaluating the OCT images, and masked to OCT&#xD;
      readings when evaluating fundus photographs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity Corrected for Enrichment</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity corrected for enrichment using logistic regression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity Corrected for Enrichment</measure>
    <time_frame>Day 1</time_frame>
    <description>Specificity corrected for enrichment using logistic regression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Sensitivity</measure>
    <time_frame>Day 1</time_frame>
    <description>The sensitivity observed without adjustment by logistic regression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Specificity</measure>
    <time_frame>Day 1</time_frame>
    <description>The specificity observed without adjustment by logistic regression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sufficient vs. Insufficient Image Quality Output From IDx-DR</measure>
    <time_frame>Day 1</time_frame>
    <description>Image-ability, defined as the percentage of participants with a completed reading center grading and a disease level output from the investigational device (IDx-DR)</description>
  </primary_outcome>
  <enrollment type="Actual">900</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic - sampling method: non-probability sequential, invitation to volunteer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of diabetes mellitus, e.g.:&#xD;
&#xD;
               1. Having met the criteria established by either the World Health Organization (WHO)&#xD;
                  or the American Diabetes Association (ADA)&#xD;
&#xD;
               2. Hemoglobin A1c (HbA1c) ≥ 6.5%&#xD;
&#xD;
               3. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)&#xD;
&#xD;
               4. Oral Glucose Tolerance Test (OGTT) with two-hour plasma glucose (2-hr PG) ≥ 200&#xD;
                  mg/dL (11.1 mmol/L), using the equivalent of an oral 75 g anhydrous glucose dose&#xD;
                  dissolved in water&#xD;
&#xD;
               5. Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose&#xD;
                  (RPG) ≥ 200 mg/dL (11.1 mmol/L)&#xD;
&#xD;
          2. Age 22 or older&#xD;
&#xD;
          3. Understand the study and volunteer to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persistent vision loss, blurred vision, or floaters.&#xD;
&#xD;
          2. Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative&#xD;
             retinopathy, radiation retinopathy, or retinal vein occlusion.&#xD;
&#xD;
          3. History of laser treatment of the retina or injections into either eye, or any history&#xD;
             of retinal surgery.&#xD;
&#xD;
          4. Currently participating in another investigational eye study and actively receiving&#xD;
             investigational product for DR or DME.&#xD;
&#xD;
          5. Participant has a condition that, in the opinion of the investigator, would preclude&#xD;
             participation in the study (e.g., unstable medical status including blood pressure or&#xD;
             glycemic control, microphthalmia or previous enucleation).&#xD;
&#xD;
          6. Participant is contraindicated for imaging by fundus imaging systems used in the&#xD;
             study:&#xD;
&#xD;
               -  Participant is hypersensitive to light&#xD;
&#xD;
               -  Participant recently underwent photodynamic therapy (PDT)&#xD;
&#xD;
               -  Participant is taking medication that causes photosensitivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02963441/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02963441/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From January 2017 to July 2017, 900 participants were prospectively enrolled in this observational study at 10 primary care practice sites throughout the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intent to Screen Population</title>
          <description>Prospective study participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="900"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="819"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol violation or withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ungradeable by FPRC or IDx</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>IDx-DR insufficient quality</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of analyzable study participants</population>
      <group_list>
        <group group_id="B1">
          <title>Effective Analysis Population</title>
          <description>All subjects with a reading center reference standard and AI output (population that is available for statistical analysis).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="819"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="566"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="680"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="523"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity Corrected for Enrichment</title>
        <description>Sensitivity corrected for enrichment using logistic regression</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analyzable Study Population</title>
            <description>Participants that had reading center grading and AI disease outputs that were available for statistical analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Corrected for Enrichment</title>
          <description>Sensitivity corrected for enrichment using logistic regression</description>
          <units>percentage of true positives</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="81.8" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity Corrected for Enrichment</title>
        <description>Specificity corrected for enrichment using logistic regression</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analyzable Study Population</title>
            <description>Participants that had reading center grading and AI disease outputs that were available for statistical analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity Corrected for Enrichment</title>
          <description>Specificity corrected for enrichment using logistic regression</description>
          <units>percentage of true negatives</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="88.3" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Sensitivity</title>
        <description>The sensitivity observed without adjustment by logistic regression</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analyzable Study Population</title>
            <description>Participants that had reading center grading and AI disease outputs that were available for statistical analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Sensitivity</title>
          <description>The sensitivity observed without adjustment by logistic regression</description>
          <units>percentage of true positives</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" lower_limit="81.9" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Specificity</title>
        <description>The specificity observed without adjustment by logistic regression</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analyzable Study Population</title>
            <description>Participants that had reading center grading and AI disease outputs that were available for statistical analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Specificity</title>
          <description>The specificity observed without adjustment by logistic regression</description>
          <units>percentage of true negatives</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="86.9" upper_limit="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sufficient vs. Insufficient Image Quality Output From IDx-DR</title>
        <description>Image-ability, defined as the percentage of participants with a completed reading center grading and a disease level output from the investigational device (IDx-DR)</description>
        <time_frame>Day 1</time_frame>
        <population>Image-ability, defined as the percentage of participants with a completed FPRC grading and a disease level IDx-DR output</population>
        <group_list>
          <group group_id="O1">
            <title>Analyzable Study Population</title>
            <description>Participants with the reading center results needed for study analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Sufficient vs. Insufficient Image Quality Output From IDx-DR</title>
          <description>Image-ability, defined as the percentage of participants with a completed reading center grading and a disease level output from the investigational device (IDx-DR)</description>
          <population>Image-ability, defined as the percentage of participants with a completed FPRC grading and a disease level IDx-DR output</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="852"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="94.0" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Day 1 to 30 days after last study contact.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enrolled Population</title>
          <description>All study subjects enrolled into the clinical study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="900"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye edema</sub_title>
                <description>Bilateral swelling in eyes post dilation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <description>burning sensation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemic Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <description>symptoms occurred after eye drops instilled</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="900"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study, Institution will be free to publish the methods, data and results of the Study</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>IDx President, Dr. Michael Abramoff</name_or_title>
      <organization>IDx LLC</organization>
      <phone>319-248-5620</phone>
      <email>info@eyediagnosis.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

